**ETCTN Trials by Disease/ Treatment Area: Leukemia**

- **Leukemia**
  - **Lymphocytic**
    - Relapsed or refractory CD19+ precursor B-lymphoblastic leukemia
    - CD3+ acute lymphoma, or poor-risk chronic subtypes of Adult T-Cell Lymphoma/Leukemia

- **Myelogenous**
  - Relapsed or refractory AML, myelodysplastic syndrome, or chronic myelomonocytic leukemia
  - AML with wild-type p53
  - AML in complete remission
  - AML associated with antecedent myeloproliferative disorder
  - Mutated AML
  - AML (front line therapy)
  - MDS or oligoblastic AML

- **Myelodysplastic syndrome**
  - MDS or oligoblastic AML

- **Hematologic malignancy**
  - Hematologic malignancy, not otherwise stated

* 10030: MRD-ERASER 1: Randomized Phase 2 Study of the Anti-PD-L1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia

* 10355: Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma with EPOCH and Lenalidomide

10026: A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia

10247: A Randomized Phase II Trial of MLN4924 (Pevonedistat) with Azacitidine Versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia

10246: A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

10237: A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents

10273: A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia

10264: The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

10075: A Phase 1B Study of AMG-232 in Combination with Decitabine in Acute Myeloid Leukemia

9706: Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)

10147: A Phase II Randomized Study of Topotecan/Carboplatin with or Without Veliparib or Placebo in Advanced Myeloproliferative Disorders and CMML

10200: A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23- Rearranged Acute Myeloid Leukemia

* 10317: Checkpoint Blockade to Overcome Resistance in TP53 Mutated Acute Myeloid Leukemia

10212: A Phase 1b/2 Study of Pinometostat in Combination with Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with MLL Rearrangement

* 10300: Randomized Phase 2 Study of the Anti-PD-L1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia

* 10334: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitidine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy

10009: A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure

10014: A Pilot Study of Azatcilizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: July 15, 2019